Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 8:ciaa546. doi: 10.1093/cid/ciaa546

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 1. — Concentration–response curves for chloroquine’s effect on the LPS-triggered production of TNF-α, IL-6, CCL2, and CCL3. Human lung explants from 6 to 7 patients were stimulated with LPS in the absence or presence of chloroquine (0.001–1 mM). *P < .05, **P < .01, ***P < .001 compared with LPS alone. Abbreviations: CCL2, monocyte chemoattractant protein 1; CCL3, macrophage inflammatory protein 1α; IL-6, interleukin-6; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor α.